Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

25.32
-0.2200-0.86%
Volume:476.59K
Turnover:12.15M
Market Cap:3.22B
PE:-6.55
High:25.67
Open:25.55
Low:25.18
Close:25.54
52wk High:31.74
52wk Low:12.09
Shares:127.33M
Float Shares:89.84M
Volume Ratio:0.37
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:6.95
PE(LYR):-7.70

Loading ...

Earning Preview: Arcus Biosciences Inc. this quarter’s revenue is expected to decrease by 19.31%, and institutional views are bullish

Earnings Agent
·
Apr 28

Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes

Simply Wall St.
·
Apr 27

Arcus Biosciences grants new hire options for 4,200 shares, RSUs for 2,100 shares

Reuters
·
Apr 25

Arcus Biosciences rises 12.2%

TIPRANKS
·
Apr 22

Arcus Biosciences schedules conference call on quarterly results, pipeline update

Reuters
·
Apr 22

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

MT Newswires Live
·
Apr 22

Merck setback has positives and negatives for Arcus Biosciences, says BofA

TIPRANKS
·
Apr 22

Merck study miss not a read for Arcus, says H.C. Wainwright

TIPRANKS
·
Apr 22

Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Apr 21

Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Arcus Biosciences Discontinues Lung Cancer Trial With Gilead

Dow Jones
·
Apr 20

BRIEF-Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility

Reuters
·
Apr 20

Arcus Biosciences Inc - Gilead's Option Rights Under Collaboration Agreement to End July 14, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 20

Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due to Futility - SEC Filing

THOMSON REUTERS
·
Apr 20

Arcus Biosciences discontinues Phase 3 STAR-121 lung cancer trial for futility

Reuters
·
Apr 20

Arcus Biosciences grants new employee stock options for 7,850 shares under inducement plan

Reuters
·
Apr 10

Wedbush raises Arcus Biosciences price target to $41, adds to Best Ideas List

TIPRANKS
·
Apr 02

Arcus Biosciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 02

Arcus Biosciences Inc : Wedbush Raises Target Price to $41 From $37

THOMSON REUTERS
·
Apr 02